@dansfera: The FDA dropped their final guidance on ICH E6R3, and the industry is buzzing about what it actually means for clinical sites. While technically non-binding for US sites, this guidance reflects the agency’s current thinking, and sponsors are treating it as the gold standard. Ignoring these updates isn't really an option if you want to stay compliant. Here is the official breakdown on what everyone in clinical research needs to know right now. #ClinicalResearch #FDA #GCP #ClinicalTrials #RegulatoryCompliance